Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083263336> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2083263336 endingPage "256" @default.
- W2083263336 startingPage "246" @default.
- W2083263336 abstract "One of the key characteristics of inflammation is the recruitment of leukocytes to the site of inflammation. Most anti-inflammatory strategies act intracellularly on the target cells, but after the cells have migrated to the site. We therefore propose that the prevention of cellular recruitment by blockade of the relevant chemokine receptor/ligand pair would present a novel therapy in that it would act upstream of the therapies currently in use. The chemokine system is a complex family of over 40 ligands and 18 receptors and as such may appear difficult to inhibit selectively. In the first part of the article we discuss the specificity mechanisms that are beginning to be unraveled which we believe occur at multiple levels. These levels of control of specificity include the temporal regulation of both the ligands and their receptors, which are under the control of pro-inflammatory cytokines; the localization of chemokines on cell surfaces through their interactions with glycosaminoglycans; differential receptor/ligand interactions; and different patterns of receptor trafficking, to name but a few. The chemokine system has been validated as providing good therapeutic targets by several approaches. In our laboratory, we have used a chemokine receptor antagonist in models of inflammation in vivo to demonstrate that this approach is successful in reducing inflammation. Chemokine receptors belong to the class of seven transmembrane spanning receptors, which have proven to be excellent targets by the pharmaceutical industry for many diseases. The number of small molecule inhibitors of chemokine receptors is rapidly growing in the patent literature, and reports both in the literature as well as conferences in the field have shown them to be effective in inflammatory disease models, as well as inhibiting HIV-1 infection. Since clinical trials will begin this year with some of these molecules, hopefully we will fairly soon have the answer of the efficacy of this therapeutic approach." @default.
- W2083263336 created "2016-06-24" @default.
- W2083263336 creator A5057932996 @default.
- W2083263336 creator A5060493134 @default.
- W2083263336 creator A5079458230 @default.
- W2083263336 date "2000-10-01" @default.
- W2083263336 modified "2023-10-16" @default.
- W2083263336 title "The strategy of blocking the chemokine system to combat disease" @default.
- W2083263336 doi "https://doi.org/10.1034/j.1600-065x.2000.17721.x" @default.
- W2083263336 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11138781" @default.
- W2083263336 hasPublicationYear "2000" @default.
- W2083263336 type Work @default.
- W2083263336 sameAs 2083263336 @default.
- W2083263336 citedByCount "81" @default.
- W2083263336 countsByYear W20832633362012 @default.
- W2083263336 countsByYear W20832633362013 @default.
- W2083263336 countsByYear W20832633362014 @default.
- W2083263336 countsByYear W20832633362015 @default.
- W2083263336 countsByYear W20832633362016 @default.
- W2083263336 countsByYear W20832633362017 @default.
- W2083263336 countsByYear W20832633362018 @default.
- W2083263336 countsByYear W20832633362022 @default.
- W2083263336 crossrefType "journal-article" @default.
- W2083263336 hasAuthorship W2083263336A5057932996 @default.
- W2083263336 hasAuthorship W2083263336A5060493134 @default.
- W2083263336 hasAuthorship W2083263336A5079458230 @default.
- W2083263336 hasConcept C12823836 @default.
- W2083263336 hasConcept C129013479 @default.
- W2083263336 hasConcept C13373296 @default.
- W2083263336 hasConcept C140944930 @default.
- W2083263336 hasConcept C170493617 @default.
- W2083263336 hasConcept C186382791 @default.
- W2083263336 hasConcept C203014093 @default.
- W2083263336 hasConcept C206615009 @default.
- W2083263336 hasConcept C2776914184 @default.
- W2083263336 hasConcept C55493867 @default.
- W2083263336 hasConcept C84913492 @default.
- W2083263336 hasConcept C86803240 @default.
- W2083263336 hasConcept C95444343 @default.
- W2083263336 hasConceptScore W2083263336C12823836 @default.
- W2083263336 hasConceptScore W2083263336C129013479 @default.
- W2083263336 hasConceptScore W2083263336C13373296 @default.
- W2083263336 hasConceptScore W2083263336C140944930 @default.
- W2083263336 hasConceptScore W2083263336C170493617 @default.
- W2083263336 hasConceptScore W2083263336C186382791 @default.
- W2083263336 hasConceptScore W2083263336C203014093 @default.
- W2083263336 hasConceptScore W2083263336C206615009 @default.
- W2083263336 hasConceptScore W2083263336C2776914184 @default.
- W2083263336 hasConceptScore W2083263336C55493867 @default.
- W2083263336 hasConceptScore W2083263336C84913492 @default.
- W2083263336 hasConceptScore W2083263336C86803240 @default.
- W2083263336 hasConceptScore W2083263336C95444343 @default.
- W2083263336 hasIssue "1" @default.
- W2083263336 hasLocation W20832633361 @default.
- W2083263336 hasLocation W20832633362 @default.
- W2083263336 hasOpenAccess W2083263336 @default.
- W2083263336 hasPrimaryLocation W20832633361 @default.
- W2083263336 hasRelatedWork W1994752012 @default.
- W2083263336 hasRelatedWork W2019143025 @default.
- W2083263336 hasRelatedWork W2050684121 @default.
- W2083263336 hasRelatedWork W2083263336 @default.
- W2083263336 hasRelatedWork W2115850686 @default.
- W2083263336 hasRelatedWork W2118526748 @default.
- W2083263336 hasRelatedWork W2153184118 @default.
- W2083263336 hasRelatedWork W2354946414 @default.
- W2083263336 hasRelatedWork W24016100 @default.
- W2083263336 hasRelatedWork W3154902925 @default.
- W2083263336 hasVolume "177" @default.
- W2083263336 isParatext "false" @default.
- W2083263336 isRetracted "false" @default.
- W2083263336 magId "2083263336" @default.
- W2083263336 workType "article" @default.